Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3,099.00    25.00 (0.81%)
Bid:
3,088.00
Ask:
3,091.00
Spread: 3.00 (0.097%)
Market Cap: £4.32b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Q1 2010 Trading Statement

28 Apr 2010 07:00

RNS Number : 9062K
Croda International PLC
28 April 2010
 



28 April 2010

 

Croda International Plc

First quarter trading statement

 

Martin Flower, Chairman of Croda International Plc, is due to provide the following update on first quarter trading at today's Annual General Meeting:

 

"At the time of our preliminary results in February we reported that the strong trading performance seen in the second half of 2009 had continued into 2010. We are now able to report record quarterly sales and profits in both Consumer Care and Industrial Specialities.

 

Group sales increased 14.7% to £264.7m (2009: £230.8m) despite adverse currency translation of 4.1%, with overall volumes increasing 26.0%.

 

Group pre-tax profit from continuing operations almost doubled to £42.4m (2009: £21.7m).

 

On a segmental basis, Consumer Care operating profit was up 20.6% to £34.6m (2009: £28.7m) despite challenging 2009 comparatives. Underlying sales increased strongly in both Personal Care and Health Care but Crop Care sales were down in line with the market. Overall sales increased to £130.0m, up 1.4% on last year's figure of £128.2m, despite the adverse currency translation.

 

Industrial Specialities reversed last year's £2.4m loss to record an operating profit of £10.5m with almost all areas seeing significant revenue and profit increases. Volumes increased dramatically and this is driving the 31% increase in revenues to £134.7m (2009: £102.6m).

 

As a consequence of the cash restructuring costs from the closures of both Bromborough and Wilton and adverse currency translation of £5.8m, net debt was little changed from the year end at £292.7m.

 

This is a very strong performance across the business and reflects both robust demand for our products globally and the benefits of the cost cutting activity we have undertaken since the acquisition of Uniqema. However, the buoyant trading conditions we have experienced have been seen across the chemical sector, suggesting an element of restocking. Furthermore, prior year comparatives do get tougher in the second half. We also expect to see raw material inflation begin to increase in many areas.

 

Notwithstanding the above, the robust trading has continued into quarter two and we remain confident of achieving significant progress throughout the remainder of 2010."

 

 

For further information, please contact:

 

Mike Humphrey, Group Chief Executive

Tel: 01405 860551

Sean Christie, Group Finance Director

Charlie Armitstead, Financial Dynamics

Tel: 07703 330 269

 

The company will host a conference call for analysts at 8.00am (BST) today:

Dial-In: +44 (0)1452 542 303

Please quote "Croda International"to gain access to the call

 

 

Croda International Plc

Unaudited income statement before tax and exceptional items

31 March 2010

£m

3 months to

3 months to

31 March

31 March

2010

2009

Change

Consumer Care

130.0

128.2

+1.4%

Industrial Specialities

134.7

102.6

+31.3%

Revenues from continuing operations

264.7

230.8

+14.7%

Consumer Care

34.6

28.7

+20.6%

Industrial Specialities

10.5

(2.4)

n/a

Operating profit from continuing operations

45.1

26.3

+71.5%

Net bank and loan interest payable

(2.8)

(4.5)

Net retirement benefit scheme financing

0.1

(0.1)

Profit before tax from continuing operations

42.4

21.7

+95.4%

Continuing operations operating margin

17.0%

11.4%

Analysis of turnover uplift for continuing operations

Continuing operations sales volumes

+26.0%

Currency impact

-4.1%

Price/mix

-7.2%

+14.7%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFFRSLIDFII
Date   Source Headline
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech
11th Jan 20233:45 pmRNSDirector/PDMR Shareholding
13th Dec 20223:04 pmRNSDirector/PDMR Shareholding
6th Dec 202212:36 pmRNSDirector/PDMR Shareholding
14th Nov 20223:33 pmRNSHolding(s) in Company
11th Nov 20222:04 pmRNSDirector/PDMR Shareholding
11th Nov 202210:37 amRNSDirector/PDMR Shareholding
11th Nov 202210:33 amRNSDirector/PDMR Shareholding
8th Nov 202211:23 amRNSDirector/PDMR Shareholding
7th Nov 20226:11 pmRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.